

Index

Pharmacological Reviews

Volume 41

1989

- Accessory cells, pharmacological effects on immune function, cyclosporine, 377
- Acetylcholine, action of ethanol, 516
- N*-Acetylcysteine, isophosphamide and, effects of combinations (fig.), 129
- Adenosine, action of ethanol, 518
- Adenosine diphosphate ribose, adenosine-5'-diphosphate and, isoboles (fig.), 96
- Adenosine monophosphate, cyclic, adenylate cyclase and, action of ethanol, 519
- Adenylate cyclase
 cAMP levels, action of ethanol, 519
 system, receptors and, 448
- β -Adrenoceptor, desensitization, 442
- Albutoin, trimethadione and, isobole (fig.), 97
- Alcohol, ethanol action, 495
- Alloantibodies, pharmacological properties of cyclosporine, 265
- Allografts
 classical, 283
 new, 288
 reactivity (fig.), 298
- Amines, biogenic, 517
- Amino acids
 excitatory
 binding sites, 156
 receptors, vertebrate central nervous system, 145
 explanation of terms (table), 146
 sulfur-containing, 148
- γ -Aminobutyric acid
 -activated chloride channels, 511
 antagonism, electrophysiology, 513
 ethanol effects, 510
 release and reuptake, 514
- α -Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, excitatory amino acid receptors, vertebrate central nervous system, 147
- Anticholinergic agents, neuropeptide modulation, central vestibular circuits, 69
- Antigen-presenting cells
 cellular activation, cyclosporine, 417
 cyclosporine and adjunctive suppression, 302
- Antigens
 presentation, cyclosporine (table), 381
 processing and presentation, 379
 viral, 264
- Anti-human lymphocyte serum, pharmacological effects on immune function, cyclosporine, 387
- Antiseizure agents, neuropeptide modulation, central vestibular circuits, 71
- Aplysia*, ethanol effects, 506
- Arginine-vasopressin
 barrel rotation
 hazard functions (fig.), 59, 60
 statistical differences, peptide dose (table), 57
 barrel rotation and mortality (fig.), 56, 57
 barrel rotation and peptide dose, 65
 barrel rotation latency (table), 62
 dose-response relation, 69
 frequency histogram (table), 63
 hazard epochs as states of destabilization (table), 61
 hazard functions for barrel rotation (fig.), 77, 79
 incidence and temporal dynamics, motor dysfunction, 55
 incidence of mortality (fig.), 63
 -induced barrel rotation, 69
 initial phase hazard parameter (fig.), 62
 lethal convulsions and barrel rotation, 64
 model for barrel rotation, 78
 multiple regression analysis of incidence of mortality (table), 64
 neurotoxicity, 64
 potential sites of action, 81
 statistical differences, incidence of mortality (table), 58
- Arylcyclohexylamines, excitatory amino acid receptors, central nervous system, 152
- L*-Aspartate, excitatory amino acid receptors, vertebrate central nervous system, 148
- Autoantibodies, pharmacological properties of cyclosporine, 266
- Autoimmune disease
 clinical, cyclosporine (table), 339
 cyclosporine, 318
 experimental models, 322
 summary of results with cyclosporine (table), 319
- Autoimmunity
 antibody-mediated, 331
 interactions of cyclosporine, suppressor cells, 337
 psoriasis, 336
 T cell-mediated, 330
- Autonomic nervous system, excitatory amino acid receptors, 170
- Autoradiography, excitatory amino acid receptors, central nervous system, 159
- Bacteria
 extracellular, 348
 facultative intracellular, 345
- Balaban, Carey D., Starčević, Vesna P., and Severs, Walter B. Neuropeptide modulation of central vestibular circuits, 53
- Barbiturates, excitatory amino acid receptors, central nervous system, 155
- Basal ganglia
 midbrain sites and forced movements, 75
 neuropeptide modulation, central vestibular circuits, 84
- B cells
 pharmacological effects on immune function, cyclosporine, 392
 single, amplification, variable region sequence (fig.), 543
- Behavior, excitatory amino acid receptors, 193
- Benz(f)isoquinoline, benzomorphans and, excitatory amino acid receptors, central nervous system, 153
- Berenbaum, M. C. What is synergy?, 93
- Blood, transfusion, cyclosporine and, 304
- Borel, J. F., Di Padova, F., Mason, June, Quesniaux, Valérie, Ryffel, B., and Wenger, R. Pharmacology of cyclosporine (Sandimmune). I. Introduction, 239

- Borel, J. F. Pharmacology of cyclosporine (Sandimmune). IV. Pharmacological properties in vivo, 259
- Bradykinin, antagonists, neuropeptide modulation, central vestibular circuits, 69
- Brain
- basal forebrain, bed nucleus, stria terminalis, 84
 - function, ethanol metabolism, 522
 - midbrain sites and forced movements, 75
- Brainstem, excitatory amino acid receptors, central nervous system, 181
- Bromocriptine, cyclosporine and, 305
- Cajal, interstitial nucleus, 85
- Calcium
- intracellular, release, ethanol effects, 508
 - mobilization, cellular activation, cyclosporine, 409
 - permeability, excitatory amino acid receptors, central nervous system, 162
 - sodium exchange, ethanol effects, 510
- Calcium channels
- classification, 216
 - ethanol effects, 508
 - invertebrate cells, 216
 - modulation by protein kinase C activation (table), 217
- 3-(2-Carboxypiperazin-4-yl)-propenyl-1-phosphonate, excitatory amino receptors, central nervous system, 151
- Carminomycin, cyclophosphamide and, isoboles (fig.), 127
- Cations, divalent, excitatory amino acid receptors, central nervous system, 151, 162
- Cell death, neuronal, 194
- Central nervous system
- initial actions, mechanism of action, ethanol, 489
 - mammalian, hippocampus, ethanol effects, 501
 - opioid tolerance and dependence, 465
 - vertebrate, excitatory amino acid receptors, 143
 - vertebrate neurones, 219
- Cerebellar cortex, neuropeptide modulation, central vestibular circuits, 83
- Cerebellum
- cortical stimulation and lesions, 74
 - ethanol effects, 503
 - single-unit activity, 496
 - excitatory amino acid receptors, 192
 - central nervous system, 179
 - lesions, 72
- Chlamydia*, cyclosporine, 345
- Chlormazine methiodide, neuropeptide modulation, central vestibular circuits, 69
- Chloride channels, ethanol effects, 508
- Cholecystokinin, substance P and bradykinin antagonists, 68
- Cocaine
- behavioral determinants, 15
 - behavioral pharmacology, 10
 - behavioral tolerance, 17
 - botany and history, 4
 - dependence-producing effects, 34
 - discriminative stimulus effects, 20
 - central mediation, 22
 - epidemiology, 7
 - hotline survey data (table), 8
 - measures of reinforcing efficacy, 26
 - medical uses, 6
 - mood-altering properties, 18
 - motor behavior, 8
 - neurobiology of sensitization, 13
 - pharmacokinetics and metabolism, 6
 - "pharmacological kindling," 14
 - pharmacology, relation to abuse, 3
 - reinforcement
 - neurobiology, 29
 - other potential measures, 33
 - reinforcing effects, 23
 - schedule-controlled behavior, 15
 - schedules of reinforcement, 24
 - self-administration methods, 23
 - tolerance, 21
 - toxicity, 35
 - treatment
 - pharmacological approaches, 40
 - psychological and behavioral approaches, 38
 - trends in prevalence of use (table), 7
- Collingridge, Graham L., and Lester, Robin A. J. Excitatory amino acid receptors in the vertebrate central nervous system, 143
- Complement, coagulation cascades and, serum mediators, 549
- Convulsions
- drug model, 175
 - neuropeptide modulation, central vestibular circuits, 55
- Cortex, opioid tolerance and dependence, 475
- Cyclophilin, molecular target for cyclosporine action, 416
- Cyclophosphamide, carminomycin and, isoboles (fig.), 127
- Cyclosporin A
- chemical synthesis, 245
 - chemistry, 243
 - effects on antibody responses in mouse (table), 263
 - modifications and structure-activity relationships, 245
 - structure (fig.), 244
 - suppressive effect (fig.), 261
- Cyclosporine
- adjunctive suppression of APC function, 302
 - allogeneic and xenogeneic organ transplantation (table), 284
 - antibody-mediated immune response (fig.), 263
 - antigen presentation and (table), 381
 - binding proteins (table), 415
 - cellular activation, 407
 - cellular uptake, 414
 - cellular uptake (fig.), 415
 - clinical autoimmune diseases (table), 339
 - combined with ALS/ATG or monoclonal antibodies, 301
 - combined with other chemical immunosuppressants, 300
 - development in brief (table), 241
 - effects on immune response (fig.), 412
 - eleven amino acid residues (fig.), 251
 - fungicidal and antiparasitic effects (table), 349
 - immunochemistry and monitoring, 249
 - interactions with suppressor cells, autoimmunity, 337
 - long-term protective effect, murine schistosomiasis (fig.), 350
 - major functions of mononuclear phagocytes (table), 378
 - mechanism of action, delayed-type hypersensitivity reactions, 273
 - mechanism of action in vivo (fig.), 283
 - modulation of host defenses, 339
 - monitoring, 254
 - clinical relevance, 255
 - mono-drug therapy, 299
 - multiple molecular targets, 415
 - natural, two cell-mediated immune response (table), 270
 - number of publications (fig.), 240
 - pathophysiology and toxicology, humans and animals, 423
 - pharmacokinetics, 251
 - pharmacological effects, immune function, 373
 - pharmacological properties, 259
 - pharmacological spectrum, 240
 - pharmacology, 239
 - summary of antiparasitic effects (table), 350
 - synergistic action, anti-IL-2R monoclonal antibody, 301

- therapy, 281
 three-dimensional model (fig.), 252
 tolerance (fig.), 312
 tolerance induction (fig.), 308
 Cytochromes P450, molecular biology (table), 92
 Cytokines
 human, overview (table), 411
 monoclonal antibodies, pharmacological agents, 551
 Cytomegalovirus, cyclosporine, 341
- Deitrich, Richard A., Dunwiddie, Thomas V., Harris, R. Adron, and Erwin, V. Gene. Mechanism of action of ethanol: Initial central nervous system actions, 489
 Dentate gyrus, excitatory amino acid receptors, central nervous system, 174
 Diabetes
 experimentally induced, 329
 insulin-dependent, 331, 333
 Diazepam, neuropeptide modulation, central vestibular circuits, 71
 Dibenzocycloheptenimine, excitatory amino acid receptors, central nervous system, 153
 Dioxolanes, excitatory amino acid receptors, central nervous system, 153
 Di Padova, F. Pharmacology of cyclosporine (Sandimmune). V. Pharmacological effects on immune function: In vitro studies, 373
 Di Padova, F. *See* Borel et al., 239
 Disequilibrium syndromes, barrel rotation, 76
 DNA, recombinant, monoclonal antibodies, pharmacological agents, 542
 Drugs
 combinations of, 94
 complex environmental mixtures, 130
 concentration- and response-addition, 118
 design using monoclonal antibodies, 540
 direct search methods, 127
 direct search of response surface (fig.), 128
 response surface modelling, 126
 therapeutic effect with combinations (fig.), 124
 variation with time in concentrations, 123
 Dunwiddie, T. V. *See* Deitrich, et al., 489
- Encephalomyelitis, experimental allergic, various stages (fig.), 325
 Endocrine cells, modulation of ion channel activity, 222
 Epilepsy, excitatory amino acid receptors, 193
 Epileptogenesis, high K⁺-induced, 175
 Equilibrium, midbrain sites and forced movements, 75
 Erwin, V. G. *See* Deitrich, et al., 489
 Ethanol
 effects, 493
 mechanism of action, initial central nervous system actions, 489
 membrane fluidity, 491
 metabolic effects, 522
 neuronal electrical activity, 496
 neuropeptides and, 523
 voltage or second-messenger gated ion channels, 505
 Exocrine glands, opioid tolerance and dependence, 439
- Fibroblasts, cellular activation, cyclosporine, 417
 Fischman, M. W. *See* Johansen and Fischman, 3
 Fleming, W. M. *See* Johnson and Fleming, 435
 Fluorazepam, hexobarbital and, isobole (fig.), 103
- Genes
 amplification technology
 generation, recombinant antibodies (fig.), 543
 immunoengineering (fig.), 543
 cellular activation, cyclosporine, 409
 control of expression, cellular activation, cyclosporine, 412
 Glial cells, vertebrate central nervous system, 227
 Glutamate
 action of ethanol, 515
 effect of ions on binding, 156
 L-Glutamate, excitatory amino acid receptors, 189
 γ -D-Glutamylglycine, broad spectrum antagonists, 149
 Glycine
 antagonists (fig.), 154
 excitatory amino acid receptors, central nervous system, 162
 Grafts, composite, 290
 Graft-*vs*-host reaction, pharmacological properties of cyclosporine, 275
 Granuloma, chronic hypersensitivity pneumonitis and, 272
 Growth factor, synthesis, cellular activation, cyclosporine, 410
 Guanosine monophosphate, cyclic
 compounds reported to decrease levels (table), 521
 compounds reported to increase levels (table), 521
- Halothane, morphine and, isobole (fig.), 102
 Harris, R. A. *See* Deitrich, et al., 489
 Hematopoiesis, pharmacological effects on immune function, cyclosporine, 392
 Hemodynamics, systemic, cyclosporine, 425
 Hemopoietic cells, cellular activation, cyclosporine, 417
 Hepatitis virus, cyclosporine, 341
 Hepatocytes, cellular activation, cyclosporine, 417
 Herpes simplex virus, cyclosporine, 340
 Hexobarbital, fluorazepam and, isobole (fig.), 103
 Hippocampus
 ethanol effects, 499, 509
 excitatory amino acid receptors, central nervous system, 171
 kindling and kindling-like phenomena, 187
 long term potentiation, 183
 mammalian central nervous system, ethanol effects, 501
 opioid tolerance and dependence, 472
 potassium channels, ethanol effects, 507
 Hypersensitivity
 delayed-type, 270
 clinical tests, 272
 cyclosporine mechanism of action, 273
 delayed-type (table), 271
 pneumonitis and chronic granuloma, 272
- Ibotenate, excitatory amino acid receptors, vertebrate central nervous system, 148
 Ifenprodil, excitatory amino acid receptors, central nervous system, 155
 Ileum, guinea pig, opioid tolerance and dependence, 454
 Immunity
 antibody-mediated, 260
 cell-mediated, 269
 Immunoinflammatory cascade, antibody inhibition (fig.), 548
 Immunosuppressants, pharmacological dose-response curves, cyclosporine, 418
 Infectious diseases, antibodies, 545
 Influenza virus, cyclosporine, 342
 Insulin
 resting or stimulated release, pancreatic tissue (table), 429
 stimulated serum, C-peptide levels, cyclosporine (table), 429
 Invertebrate cells, calcium channels, 216
 Ion channels
 biophysical properties, 215
 general properties, 215
 modulation, 215
 modulation of activity, protein kinase C enzyme family, 211

- modulation of nonpotassium, noncalcium channel activity, protein kinase C (table), 230
 second-messenger gated, ethanol effects, 505
- Irradiation, lymphoid, pharmacological properties, cyclosporine, 303
- Isoboles
 additivity envelopes, 116, 120, 121
 calculation of expected effect (fig.), 105
 effects of combinations, 112
 exponential dose-response curves, 106
 linear, 104
 linear dose-response curves, 106
 linear Hill plot (fig.), 115
 linear-log and log-log dose-response curves, 108
 observed effect (fig.), 105
 problems of curve-fitting, 113
 sigmoid dose-response curves, 108
 three different equations for same data (fig.), 114
 use of summation criterion (fig.), 105
- Isophosphamide, *N*-acetylcysteine and, effects of combinations (fig.), 129
- Johanson, Chris-Ellyn, and Fischman, Marian W. The Pharmacology of cocaine related to its abuse, 3
- Johnson, Stephen M., and Fleming, William W. Mechanisms of cellular adaptive sensitivity changes: Applications to opioid tolerance and dependence, 435
- Kainate
 channels, 165
 conductance, 164
 excitatory amino acid receptors, vertebrate central nervous system, 147
- Kidney
 cellular activation, cyclosporine, 417
 glomerular dynamics, cyclosporine (table), 424
 morphology, 425
 pathophysiology and toxicology, cyclosporine, humans and animals, 423
 tubular function, 424
- Kyneuric acid, broad spectrum antagonists, 149
- LAK cells, natural killer cells and, cyclosporine, 392
- Larrick, James W. Potential of monoclonal antibodies as pharmacological agents, 539
- Lester, R. A. J. See Collingridge and Lester, 143
- Leukocytes, cyclosporine and, 305
- Limbic system, excitatory amino acid receptors, central nervous system, 179
- Lipopolysaccharides
 antibodies, 548
 -mediated microvascular damage, cell adherence, 550
 tripartite (table), 546
- Listeria*, cyclosporine, 347
- Liver, function in humans and animals (table), 429
- Locomotion, fictive, 170
- Locus coeruleus, opioid tolerance and dependence, 469
- Lymphocytes, activation, cyclosporine (fig.), 408
- Lymphocytic choriomeningitis virus, cyclosporine, 342
- Lymphokines
 pharmacological effects on immune function, cyclosporine, 391
 secretion, 383
- Macrophages, pharmacological effects on immune function, cyclosporine, 377
- Magnesium
 concentration, excitatory amino acid receptors, 168
 -free solutions, synaptic plasticity, 190
- Major histocompatibility complex, pharmacological effects on immune function, cyclosporine, 379
- Malaria, summary of antiparasitic effects, cyclosporine (table), 350
- Mason, J. See Borel et al., 239
- Mason, June. Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals, 423
- Mecamylamine, excitatory amino acid receptors, central nervous system, 154
- N*-Methyl-D-aspartate
 antagonists (fig.), 151
 competitive antagonists (fig.), 151
 excitatory amino acid receptors, vertebrate central nervous system, 147
 "non-competitive" antagonists, 152
- Mixed lymphocyte reaction, pharmacological effects on immune function, cyclosporine, 387
- Monoclonal antibodies
 abzymes, 544
 representative chemical reactions (table), 544
 anti-cancer, 551
 anti-idiotypic, design of drugs (fig.), 541
 anti-idiotypic, 544
 ligand activity (table), 545
 therapeutic applications (table), 545
 anti-TCR/CD3, 387
 anti-thrombosis, 551
 bifunctional (table), 544
 combined with cyclosporine, 301
 fine specificity to cyclosporine, 249
 human, 541
 bacterial targets (table), 546
 chimeric and composite, schematic (fig.), 542
 viral and chlamydial and parasitic targets (table), 547
 potential as pharmacological agents, 539
 potentials for cyclosporine monitoring, 254
 probe of cyclosporine conformation, 250
 replacement therapeutics, 545
 second generation, 542
 technology, 540
 therapeutics (table), 540
- Monokines
 major functions of mononuclear phagocytes, cyclosporine (table), 378
 monoclonal antibodies, pharmacological agents, 550
- Morphinan derivatives, excitatory amino acid receptors, central nervous system, 153
- Morphine, halothane and, isobole (fig.), 102
- Motor behavior
 cocaine, 8
 neuropeptide-induced dysfunction, classification (table), 56
 vestibular dysfunction, neuropeptide modulation, 55
- Multidrug resistance, reversal, 282
- Muscle
 cardiac, modulation, ion channel activity, 229
 skeletal and cardiac
 modulation, ion channel activity, 220
 opioid tolerance and dependence, 439
 smooth, 221
 opioid tolerance and dependence, 439
- Myobacteria*, cyclosporine, 346
- Natural killer cells
 effect in man, 279
 LAK cells and, cyclosporine, 392
 pharmacological properties of cyclosporine, 275

- Natural suppressor cells, -mediated tolerance (fig.), 315
- Neocortex, excitatory amino acid receptors, 191
central nervous system, 177
- Nephritis, experimental immunological models, 327
- Nerve, vestibular, symptoms of lesions, 72
- Neuroblastoma, hybrid cell line, modulation, ion channel activity, 220
- Neurones
invertebrate, 223
vertebrate central nervous system, 219, 224
vertebrate peripheral, 227
- Neurons
cultured, excitatory amino acid receptors, 170
opioid tolerance and dependence, 439, 451
- Neuropathology, excitatory amino acid receptors, 193
- Neuropeptides
action of ethanol, 528
barrel rotation
general configuration, hazard functions, 58
hazard functions (fig.), 59
scatter plot (fig.), 59
dose-response relation, 67, 69
ethanol and, 523
-induced motor dysfunction, classification (table), 56
modulation of central vestibular circuits, 53
- Neurotensin, action of ethanol, 525
- Neurotransmission, excitatory amino acid receptors, central nervous system, 166
- Neurotransmitters, neuromodulators and, interactions with ethanol, 510
- Nishizuka, Y. *See* Shearman, et al., 211
- Nocardia*, cyclosporine, 345
- Oocytes, *Xenopus*, ethanol effects, 509
- Opioid peptide agonists, antagonists and, 68
- Opioids
action of ethanol, 524
SKF 10,047, 153
tolerance and dependence
measurement, 446
mechanisms, cellular adaptive sensitivity changes, 435
- Optic tectum, excitatory amino acid receptors, 192
- β -*N*-Oxalyl-L- α , β -diaminopropionate, excitatory amino acid receptors, vertebrate central nervous system, 148
- PAF-acether, prostaglandin E₂ and, isobole (fig.), 101
- Pancreas, function, cyclosporine, 428
- Pentylentetrazole, trimethadione and, isoboles (fig.), 102
- Peripheral nervous system, opioid tolerance and dependence, 454
- Phagocytes, mononuclear, major functions, cyclosporine (table), 378
- Pharmacological agents
limitations of antibodies (table), 541
potential of monoclonal antibodies, 539
- Phorbol esters, pharmacological effects on immune function, cyclosporine, 387
- Phosphoinositol, turnover, cellular activation, cyclosporine, 409
- Phosphatidylinositol, action of ethanol, 521
- Photobacterium phosphoreum*
fractional product method, 107
fractional survivor multiplication (fig.), 108
- Phytohemagglutinin, pharmacological effects on immune function, cyclosporine, 387
- cis*-2,3-Piperidine dicarboxylic acid, broad spectrum antagonists, 149
- Pneumonitis, chronic hypersensitivity, chronic granuloma, 272
- Polymyxin B, excitatory amino acid receptors, central nervous system, 154
- Potassium channels
calcium-dependent, ethanol effects, 507
classification, 222
modulation of activity, protein kinase C activation (table), 225
voltage-dependent, ethanol effects, 506
- Potentials
dual-component EPSPs, 168
ethanol effects, 504
membrane, opioid tolerance and dependence, 453
- Propionibacteria*, cyclosporine, 348
- Prostaglandin E₂, PAF-acether and, isobole (fig.), 101
- Prostaglandins
action of ethanol, 518
pharmacological effects on immune function, cyclosporine, 377
-thromboxane system, cyclosporine (table), 427
- Prostanoids
release from renal and vascular tissue (table), 428
urinary excretion (table), 428
- Protein, phosphorylation, action of ethanol, 519
- Protein kinase C
activation, cyclosporine, 409
distribution, 214
duration of effect, 230
enzyme family
modulation, ion channel activity, 211
structural heterogeneity, 212
enzymological properties, 213
integration, other second-messenger systems, 231
modulation of ion channel activity, 215
modulation of potassium channel activity (table), 225
predicted primary structure of subspecies (fig.), 213
subspecies (table), 213
- Proteins, induction after T cell activation (table), 410
- Pseudodipeptide A, pseudodipeptide B and (fig.), 246
- Psoriasis, clinical model of autoimmunity, 336
- Purkinje cells, photomicrographs of degeneration (fig.), 65
- Pylonephritis*, cyclosporine, 348
- Quesniaux, Valérie F. Pharmacology of cyclosporine (Sandimmune). III. Immunochemistry and monitoring, 249
- Quesniaux, V. *See* Borel et al., 239
- Quinolate, excitatory amino acid receptors, vertebrate central nervous system, 148
- Quinolinic acid, neuropeptide modulation, central vestibular circuits, 86
- Quisqualate
channels, 165
conductance, 164
excitatory amino acid receptors, vertebrate central nervous system, 147
- Radioimmunoassay
cyclosporine immunochemistry and monitoring, 254
polyclonal antibodies, 255
- Receptors
adenylate cyclase system, 448
L-APB, 176
cytokine, overview (table), 411
excitatory amino acid
conductance mechanisms, 160
subtypes, agonists and antagonists (table), 147
vertebrate central nervous system, 143
excitatory non-NMDA type amino acid, antagonists (fig.), 150
GABA, action of ethanol, 513
growth factor, cellular activation, cyclosporine, 410
interleukin, cellular activation, cyclosporine, 411
interleukin 2
cyclosporine, 384
pharmacological effects, cyclosporine, 391

- kainate, central nervous system, 158
 nicotinic, desensitization, 441
 NMDA
 action of ethanol, 515
 central nervous system, 157
 synaptic plasticity, 189
 non-NMDA, blockade, synaptic transmission, 176
 PCP, NMDA antagonists (fig.), 152
 presynaptic, 170
 quisqualate, central nervous system, 158
 Red blood cells, antibodies to antigens, 545
 Renin
 plasma activity, cyclosporine (table), 427
 tissue, cyclosporine (table), 427
 Renin-angiotensin system, pathophysiology and toxicology, cyclosporine, 426
 Retina, excitatory amino acid receptors, central nervous system, 181
 RNA, second messenger systems, excitatory amino acid receptors, central nervous system, 166
 Ryffel, B. Pharmacology of cyclosporine. VI. Cellular activation: Regulation of intracellular events by cyclosporine, 407
 Ryffel, B. *See* Borel et al., 239
 Schistosomiasis
 long-term protective effect, cyclosporine (fig.), 350
 summary of antiparasitic effects, cyclosporine (table), 350
 Sekiguchi, K. *See* Shearman, et al., 211
 Serum, mediators, complement and coagulation cascades, 549
 Severs, W. B. *See* Balaban, et al., 53
 Shearman, Mark S., Sekiguchi, Kazuo, and Nishizuke, Yasutomi. Modulation of ion channel activity: A key function of the protein kinase family, 211
 Stitzel, Robert E. Tribute to James A. Bain, 1
 Sodium, -calcium exchange, ethanol effects, 510
 Sodium channels, voltage-dependent, ethanol effects, 506
 Somatotropin release-inhibiting factor
 barrel rotation
 hazard functions (fig.), 59, 60
 statistical differences, peptide dose (table), 57
 barrel rotation and mortality (fig.), 56, 57
 barrel rotation latency (table), 62
 dose-response relation, 66, 69
 frequency histogram (fig.), 63
 hazard epochs as states of destabilization (table), 61
 hazard functions for barrel rotation (fig.), 77, 79
 incidence and temporal dynamics, motor dysfunction, 55
 incidence of mortality (fig.), 63
 -induced barrel rotation, 69
 initial phase hazard parameter (fig.), 62
 lethal convulsions and barrel rotation, 64
 model for barrel rotation, 78
 neurotoxicity, 64
 photomicrographs of degenerating Purkinje cells (fig.), 65
 potential sites of action, 81
 statistical differences, incidence of mortality (table), 58
 Spinal cord
 action of ethanol, 503
 effects of non-NMDA and NMDA antagonists, 167
 opioid tolerance and dependence, 465
Staphylococcus, *Streptococcus* and, cyclosporine, 348
 Starčević, V. P. *See* Balaban, et al., 53
 Striatum
 mesencephalic nuclei and, 180
 opioid tolerance and dependence, 474
 Substance P, cholecystokinin and bradykinin antagonists, 68
 Substantia nigra
 midbrain sites and forced movements, 75
 neuropeptide modulation, central vestibular circuits, 84
 ventral tegmental area and, ethanol effects, 499
 Synapse, transmission, ethanol effects, 501, 503
 Synaptic plasticity
 agonist-induced, 188
 ethanol effects, 504
 excitatory amino acid receptors, 183
 induction of long term potentiation (fig.), 185
 Mg²⁺-free solutions, 190
 Synergy
 antagonism and potentiation (fig.), 98
 assessing interactions, 99
 definition, 93
 isobole method, 123
 mechanistic and empirical models, 95
 terminology and definitions, 99
 therapeutic (fig.), 126
 T cells
 activation, 382, 408
 induction of proteins (table), 410
 activation (fig.), 409
 clones, cyclosporine, 390
 locomotion, 386
 -mediated autoimmunity, 330
 -mediated cytotoxicity, 276
 suppressor activity (table), 315
 Thalamus, excitatory amino acid receptors, central nervous system, 180
 Thermodynamics, ethanol action, 492
 Thromboxane, -prostaglandin system, cyclosporine (table), 427
 Thymus, -dependent and -independent antigens, 262
 Thyrotropin-releasing hormone, action of ethanol, 527
 Toxins, excitatory amino acid receptors, central nervous system, 155
 Transplantation
 allogeneic and xenogenic (table), 284
 organ, immunosuppression (fig.), 299
 organ and tissue grafting, 283
 Trimethadone
 albutoin and, isobole (fig.), 97
 pentylene-tetrazole and, isoboles (fig.), 102
 Tuberculin, skin delayed-type hypersensitivity reaction (table), 271
 Tumor cells, growth, pharmacological properties, cyclosporine, 280
 Uveitis
 experimental autoimmune, 325
 spontaneous posterior, 334
 Vas deferens, mouse, 463
 Ventral tegmental area, substantia nigra and, ethanol effects, 499
 Vestibular system
 central circuits, neuropeptide modulation, 53
 dysfunction, barrel rotation, 71
 nuclei and fastigial nucleus, 82
 Wenger, Roland M. Pharmacology of cyclosporine (Sandimmune). II. Chemistry, 243
 Wenger, R. *See* Borel et al., 239
 White blood cells, antibodies to antigens, 545
 Xenografts, allogeneic transplantation, 290